Posts tagged with “Ascot Cardiology Group”
Electrophysiology at Ascot Cardiology Group
Click here for Patient information on the Electrophysiology Study (EPS) offered at Ascot Cardiology Group. Transcript: Dr Patricia Ding: Morning everyone, I’m Patricia Ding, Cardiologist. I’m here with Dr. Warwick Jaffe, Interventional Cardiologists from Ascot Cardiology. So Warwick, I hear that we’ve got some new electrophysiology services available at Ascot Angiography. Can you tell ...
Management of atrial fibrillation in primary care setting, the ALL-IN trial
Transcript: Dr Warwick Jaffe: Patricia, can you tell me what the trial was about? Dr Patricia Ding: Right, so this is a trial called ALL-In Trial conducted in Netherlands, involving 26 GP practices. They cluster randomised them to the integrated care group versus the usual care group. There were about 1,200 patients with 500 also ...
Dr Warwick Jaffe on current lipid management
Transcript: Dr Patricia Ding: Right. Good morning. My name is Patricia Ding. I’m one of the cardiologists at Ascot Cardiology. I’m here with Dr. Warwick Jaffe, Interventional Cardiologist from Ascot Cardiology. Morning, Warwick. Dr Warwick Jaffe: Morning, Patricia. Dr Patricia Ding: So, and tell us about the current state of play for lipid management. Dr ...
ECG Treadmill, training and support provided to TTM Hospital, Samoa
Ascot Cardiology Group Interventional Cardiologist Dr Warwick Jaffe and Nurse Mela Yudilevich travelled to Apia, Samoa this January as part of their ongoing commitment to train and support local medical staff in cardiac care. Dr Jaffe and the Ascot Cardiology Group team have continued to work closely with the Samoan Government over many years, visiting ...
Oral anticoagulation with Antiplatelet Therapy
An Update on Oral anticoagulation with Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Interventions The challenge of managing atrial fibrillation in patients who have undergone percutaneous coronary intervention for the treatment of coronary disease, is one widely shared and fraught throughout the medical field. Given the emergence of noval oral anticoagulants (NOAC) and updated current ...
Restoring the Rhythm . . . Atrial fibrillation under the scope
The global burden of atrial fibrillation remains unknown, but in New Zealand it is estimated that AF affects a minimum of five percent of the population. Atrial fibrillation is touted as the most common cardiac arrhythmia and complications can be severe – increased risk of stroke, heart failure, myocardial infarction and dementia. Management of atrial ...
Heart Failure Therapies in Focus . . . Cardiac Resynchronisation
Worldwide cardiologists and doctors alike are vested in therapies to combat heart failure and explore measures to improve the quality of life for patients – new implanted device based therapies are under active investigations- including devices that can modulate cardiac contractility, and multiple other modes to alter vagal tone. In an ever-evolving landscape of treatment ...
Heart Failure Complexities . . . A ‘black box’ of treatment measures
Around the globe, in developed countries, 1-2% of the adult population have heart failure, rising to over ten percent in those aged over 70 years. Heart failure occurs not just with reduced left ventricular ejection fraction, but also with preserved ejection fraction.– with figures steadily climbing year-on-year. However, despite the prevalence of modern-day interventions – ...
Cardiovascular Movements and Measures . . . Looking back, moving forward
Therapy treatments for cardiovascular conditions have varied in significance over the past 100 years. Post mid-1950s, experimentation in the field has seen both age-old and progressive therapy treatments come to the fore. Here Dr Tim Glenie reveals trials and tribulations behind two cardiovascular treatments that have created decades of waves across the medical world. Harking ...
Treating Hypertension Beyond Genomics . . . Personalised care and technology in focus
Treating the world’s largest ‘silent killer’ extends well beyond drug intervention, guidelines and textbook literature. Here Ascot Cardiology Group Cardiologist Dr Patrick Gladding provides insight into technological advances in blood pressure monitoring and ECG sensitivities, and the key role personalisation plays in effectively treating patients with hypertension. “Personalised medicine is more than genomics, it’s also wireless ...
Cardiovascular Therapies 50’s Forwards . . . Where we’ve come from
To many, anything that pre-dated 1990 may seem ancient – bygone eras of rock’n’roll, big hair and cheese fondue – however the past 40-years has hailed huge steps forward in cardiovascular technologies. As Dr Tim Glenie explains, breakthrough technologies in yester-years has carved a path for future advances in treatments and measures. Cardiac catheterisation has ...
Hypertension Guidelines . . . Analysis, applications and what to make of it all?
Hypertension is the world’s most common modifiable risk factor for cardiovascular disease and death. Globally, it is estimated that more than one billion adults have hypertension, and this number could reach one-and-half billion by 2025. Given that hypertension has no symptoms but accounts for over nine million deaths annually, it is known as the “silent ...
Larry Williams and Dr Jaffe video on BVS
Join Newstalk ZB’s Larry Williams as he discusses Bioresorbable Vascular Stent technology with Dr Warwick Jaffe of the Ascot Cardiology Group. Filmed on-site at Ascot Hospital, Greenlane.
GP Practice Points
Sign up for our GP Practice Points and keep up to date with the
latest news, case studies and Symposium information.